VolitionRx was one of two
companies recently highlighted in an article published in Wall St. Cheat Sheet
that emphasized the long-term impact of positive news and/or achievements in
the biotechnology industry.
“One way to offset the
current market uncertainty is to look for news driven stocks that appear to be
paving the way for future growth. This is especially true in the biotechnology
sector where one positive news announcement can help pave the way for years of
innovation. Two companies that have released recent positive announcements
include Medivation (NASDAQ:MDVN) and VolitionRx (VNRX.OB). Investors should
keep their eyes on both of these promising companies.”
To read the full article
visit http://wallstcheatsheet.com/stocks/2-biotechnology-stocks-with-a-bright-future.html/
Contributor Tom Meyer starts
with a run-down of Medivation, a biopharmaceutical company focused on the rapid
development of novel therapies to treat serious diseases, such as cancer, for
which there are limited treatment options. The company’s flagship product,
XTANDI, is FDA-approved for the treatment of patients with metastatic
castration-related prostate cancer who have previously been treated with
chemotherapy.
As an introduction to life
sciences company VolitionRx, Meyer describes the company’s goal to make
non-invasive, simple-to-use cancer blood tests similar to the tests that are
currently available for diabetics. VolitionRx’s R&D is currently centered
in Belgium as the company is initially focused on marketing its products in
Europe due to an easier path to regulatory approval there. The company’s
primary focus at this time is on the colorectal cancer market, though its
technology has the potential to be expanded into other cancers.
Meyer breaks-down into
layman’s terms the science behind VolitionRx’s cancer blood tests, as well as
the company’s ongoing clinical activities before concluding that:
“The colorectal cancer
market is in need of much better diagnostics. The current available options
include colonoscopies (invasive and expensive) and FIT/FOBT faecal-based tests
(unpleasant and don’t screen for pre-cancerous polyps). If VolitionRx can
successfully get some of its products to market, the company should see a
dramatic climb in its share price. Also, investors should begin to see a run-up
in the company’s share price as VolitionRx gets closer to revenue production.”
For more information, visit
www.volitionrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
